MLYS (Mineralys Therapeutics) FFO


MLYS Mineralys Therapeutics Inc MLYS
35 GF Score
Price $26.35
! 1 Warning Sign
View Full Analysis

What is Mineralys Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

MLYS
35GF Score
Mineralys Therapeutics Inc MLYS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score

Get the complete analysis for MLYS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.35
Price